{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T02:34:46Z","timestamp":1788834886191,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T00:00:00Z","timestamp":1653264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T00:00:00Z","timestamp":1653264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>A higher-than-usual resistance to standard sedation regimens in COVID-19 patients suffering from acute respiratory distress syndrome (ARDS) has led to the frequent use of the second-line anaesthetic agent ketamine. Simultaneously, an increased incidence of cholangiopathies in mechanically ventilated patients receiving prolonged infusion of high-dose ketamine has been noted. Therefore, the objective of this study was to investigate a potential dose\u2013response relationship between ketamine and bilirubin levels.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Post hoc analysis of a prospective observational cohort of patients suffering from COVID-19-associated ARDS between March 2020 and August 2021. A time-varying, multivariable adjusted, cumulative weighted exposure mixed-effects model was employed to analyse the exposure\u2013effect relationship between ketamine infusion and total bilirubin levels.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Two-hundred forty-three critically ill patients were included into the analysis. Ketamine was infused to 170 (70%) patients at a rate of 1.4 [0.9\u20132.0] mg\/kg\/h for 9 [4\u201318] days. The mixed-effects model revealed a positively correlated infusion duration\u2013effect as well as dose\u2013effect relationship between ketamine infusion and rising bilirubin levels (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). In comparison, long-term infusion of propofol and sufentanil, even at high doses, was not associated with increasing bilirubin levels (<jats:italic>p<\/jats:italic>\u2009=\u20090.421, <jats:italic>p<\/jats:italic>\u2009=\u20090.258). Patients having received ketamine infusion had a multivariable adjusted competing risk hazard of developing a cholestatic liver injury during their ICU stay of 3.2 [95% confidence interval, 1.3\u20137.8] (<jats:italic>p<\/jats:italic>\u2009=\u20090.01).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>A causally plausible, dose\u2013effect relationship between long-term infusion of ketamine and rising total bilirubin levels, as well as an augmented, ketamine-associated, hazard of cholestatic liver injury in critically ill COVID-19 patients could be shown. High-dose ketamine should be refrained from whenever possible for the long-term analgosedation of mechanically ventilated COVID-19 patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13054-022-04019-8","type":"journal-article","created":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T14:06:47Z","timestamp":1653314807000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Long-term ketamine infusion-induced cholestatic liver injury in COVID-19-associated acute respiratory distress syndrome"],"prefix":"10.1186","volume":"26","author":[{"given":"Pedro David","family":"Wendel-Garcia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Erlebach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Andrea","family":"Hofmaenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Camen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reto Andreas","family":"Schuepbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"J\u00fcngst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beat","family":"M\u00fcllhaupt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Bartussek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp Karl","family":"Buehler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rea","family":"Andermatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8231-0461","authenticated-orcid":false,"given":"Sascha","family":"David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,23]]},"reference":[{"issue":"2","key":"4019_CR1","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s40140-021-00440-x","volume":"11","author":"K Karamchandani","year":"2021","unstructured":"Karamchandani K, Dalal R, Patel J, Modgil P, Quintili A. Challenges in sedation management in critically ill patients with COVID-19: a brief review. Curr Anesthesiol Rep. 2021;11(2):107\u201315.","journal-title":"Curr Anesthesiol Rep"},{"issue":"12","key":"4019_CR2","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1007\/s00134-020-06307-9","volume":"46","author":"G Chanques","year":"2020","unstructured":"Chanques G, Constantin J-M, Devlin JW, Ely EW, Fraser GL, G\u00e9linas C, Girard TD, Gu\u00e9rin C, Jabaudon M, Jaber S, et al. Analgesia and sedation in patients with ARDS. Intensive Care Med. 2020;46(12):2342\u201356.","journal-title":"Intensive Care Med"},{"issue":"9","key":"4019_CR3","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1016\/j.pain.2011.03.026","volume":"152","author":"IM Noppers","year":"2011","unstructured":"Noppers IM, Niesters M, Aarts LPHJ, Bauer MCR, Drewes AM, Dahan A, Sarton EY. Drug-induced liver injury following a repeated course of ketamine treatment for chronic pain in CRPS type 1 patients: a report of 3 cases. Pain. 2011;152(9):2173\u20138.","journal-title":"Pain"},{"key":"4019_CR4","unstructured":"Sant\u00e9 A-ANdSdMedPd: K\u00e9tamine: risque d\u2019atteintes uro-n\u00e9phrologiques, endocriniennes et h\u00e9patiques graves lors d\u2019utilisations prolong\u00e9es et\/ou \u00e0 doses \u00e9lev\u00e9es \u2013 Rappel de l\u2019importance du respect du bon usage. In. Edited by Sant\u00e9 ANdSdMedPd. https:\/\/ansm.sante.fr: ANSM; 2018."},{"key":"4019_CR5","doi-asserted-by":"crossref","unstructured":"B\u00fctikofer S, Lenggenhager D, Wendel Garcia PD, Maggio EM, Haberecker M, Reiner CS, Br\u00fcllmann G, Buehler PK, Gubler C, M\u00fcllhaupt B et al. Secondary sclerosing cholangitis as cause of persistent jaundice in patients with severe COVID-19. Liver International 2021, n\/a(n\/a).","DOI":"10.1111\/liv.14971"},{"issue":"10","key":"4019_CR6","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s00134-021-06482-3","volume":"47","author":"C de Tymowski","year":"2021","unstructured":"de Tymowski C, D\u00e9pret F, Dudoignon E, Legrand M, Mallet V, Mallet V, Bock K, Mandengue PD, Dufour N, Ricard J-D, et al. Ketamine-induced cholangiopathy in ARDS patients. Intensive Care Med. 2021;47(10):1173\u20134.","journal-title":"Intensive Care Med"},{"issue":"5","key":"4019_CR7","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.jhep.2021.02.007","volume":"74","author":"V Mallet","year":"2021","unstructured":"Mallet V, Bock K, Mandengue PD, Dufour N, Voigtlaender T, Ricard J-D, Isnard P, Frochot V, Letavernier E, Moga L, et al. Intravenous ketamine and progressive cholangiopathy in COVID-19 patients. J Hepatol. 2021;74(5):1243\u20134.","journal-title":"J Hepatol"},{"issue":"9","key":"4019_CR8","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s00134-021-06445-8","volume":"47","author":"P Meersseman","year":"2021","unstructured":"Meersseman P, Blondeel J, De Vlieger G, van der Merwe S, Monbaliu D, Wauters J, Wilmer A, Gilbo N, Jochmans I, Pirenne J, et al. Secondary sclerosing cholangitis: an emerging complication in critically ill COVID-19 patients. Intensive Care Med. 2021;47(9):1037\u201340.","journal-title":"Intensive Care Med"},{"key":"4019_CR9","doi-asserted-by":"crossref","unstructured":"Force*TADT. Acute respiratory distress syndrome: the Berlin definition. Jama. 2012;307(23):2526\u20132533.","DOI":"10.1001\/jama.2012.5669"},{"key":"4019_CR10","doi-asserted-by":"crossref","unstructured":"Criteria of drug-induced liver disorders: report of an international consensus meeting. J Hepatol. 1990;11(2):272-276","DOI":"10.1016\/0168-8278(90)90124-A"},{"key":"4019_CR11","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the L: EASL Clinical Practice Guidelines: Management of cholestatic liver diseases. J Hepatol. 2009;51(2):237\u2013267.","DOI":"10.1016\/j.jhep.2009.04.009"},{"issue":"3","key":"4019_CR12","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.jhep.2019.05.009","volume":"71","author":"C de Tymowski","year":"2019","unstructured":"de Tymowski C, D\u00e9pret F, Soussi S, Nabila M, Vauchel T, Chaussard M, Benyamina M, Ferry A, Cupaciu A, Jully M, et al. Contributing factors and outcomes of burn-associated cholestasis. J Hepatol. 2019;71(3):563\u201372.","journal-title":"J Hepatol"},{"issue":"7","key":"4019_CR13","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/BF01709751","volume":"22","author":"JL Vincent","year":"1996","unstructured":"Vincent JL, Moreno R, Takala J, Willatts S, De Mendon\u00e7a A, Bruining H, Reinhart CK, Suter PM, Thijs LG. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction\/failure. Intensive Care Med. 1996;22(7):707\u201310.","journal-title":"Intensive Care Med"},{"issue":"4","key":"4019_CR14","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jhep.2021.02.036","volume":"75","author":"P Deltenre","year":"2021","unstructured":"Deltenre P, Moreno C, Tr\u00e9po E. Progressive cholangiopathy in COVID-19 patients: other possible diagnoses than ketamine-induced cholangiopathy should be considered. J Hepatol. 2021;75(4):989\u201390.","journal-title":"J Hepatol"},{"issue":"9142","key":"4019_CR15","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1016\/S0140-6736(98)04350-5","volume":"352","author":"H Jick","year":"1998","unstructured":"Jick H, Rodriguez LAG, Perez-Gutthann S. Principles of epidemiological research on adverse and beneficial drug effects. Lancet. 1998;352(9142):1767\u201370.","journal-title":"Lancet"},{"issue":"4","key":"4019_CR16","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.jclinepi.2005.01.021","volume":"59","author":"M Abrahamowicz","year":"2006","unstructured":"Abrahamowicz M, Bartlett G, Tamblyn R, du Berger R. Modeling cumulative dose and exposure duration provided insights regarding the associations between benzodiazepines and injuries. J Clin Epidemiol. 2006;59(4):393\u2013403.","journal-title":"J Clin Epidemiol"},{"issue":"9","key":"4019_CR17","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1177\/0962280220902179","volume":"29","author":"C Danieli","year":"2020","unstructured":"Danieli C, Sheppard T, Costello R, Dixon WG, Abrahamowicz M. Modeling of cumulative effects of time-varying drug exposures on within-subject changes in a continuous outcome. Stat Methods Med Res. 2020;29(9):2554\u201368.","journal-title":"Stat Methods Med Res"},{"issue":"446","key":"4019_CR18","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496\u2013509.","journal-title":"J Am Stat Assoc"},{"key":"4019_CR19","unstructured":"Team RC: R: a language and environment for statistical computing. 2013."},{"key":"4019_CR20","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jclinepi.2021.08.028","volume":"144","author":"MA Hern\u00e1n","year":"2021","unstructured":"Hern\u00e1n MA. Causal analyses of existing databases: no power calculations required. J Clin Epidemiol. 2021;144:203\u20135.","journal-title":"J Clin Epidemiol"},{"issue":"8","key":"4019_CR21","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1016\/j.cgh.2021.01.044","volume":"19","author":"B Kaltschmidt","year":"2021","unstructured":"Kaltschmidt B, Fitzek ADE, Schaedler J, F\u00f6rster C, Kaltschmidt C, Hansen T, Steinfurth F, Windm\u00f6ller BA, Pilger C, Kong C, et al. Hepatic vasculopathy and regenerative responses of the liver in fatal cases of COVID-19. Clin Gastroenterol Hepatol. 2021;19(8):1726-1729.e1723.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"4019_CR22","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.jhep.2021.06.024","volume":"75","author":"V Mallet","year":"2021","unstructured":"Mallet V, Mallet V, Bock K, Dellagi M, Tano M, Siorat V, Beeker N, Paubel P, Mandengue PD, Dufour N, et al. Reply to: Progressive cholangiopathy in COVID-19 patients: other possible diagnoses than ketamine-induced cholangiopathy should be considered. J Hepatol. 2021;75(4):990\u20132.","journal-title":"J Hepatol"},{"issue":"3","key":"4019_CR23","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/phar.2223","volume":"39","author":"PM Garber","year":"2019","unstructured":"Garber PM, Droege CA, Carter KE, Harger NJ, Mueller EW. Continuous infusion ketamine for adjunctive analgosedation in mechanically ventilated, critically ill patients. Pharmacother J Hum Pharmacol Drug Therapy. 2019;39(3):288\u201396.","journal-title":"Pharmacother J Hum Pharmacol Drug Therapy"},{"issue":"9","key":"4019_CR24","doi-asserted-by":"publisher","first-page":"e825","DOI":"10.1097\/CCM.0000000000003299","volume":"46","author":"JW Devlin","year":"2018","unstructured":"Devlin JW, Skrobik Y, G\u00e9linas C, Needham DM, Slooter AJC, Pandharipande PP, Watson PL, Weinhouse GL, Nunnally ME, Rochwerg B, et al. Clinical practice guidelines for the prevention and management of pain, agitation\/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. Crit Care Med. 2018;46(9):e825\u201373.","journal-title":"Crit Care Med"},{"issue":"1","key":"4019_CR25","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jhep.2018.03.006","volume":"69","author":"W-K Seto","year":"2018","unstructured":"Seto W-K, Mak S-K, Chiu K, Vardhanabhuti V, Wong H-F, Leong H-T, Lee PSF, Ho YC, Lee C-K, Cheung K-S, et al. Magnetic resonance cholangiogram patterns and clinical profiles of ketamine-related cholangiopathy in drug users. J Hepatol. 2018;69(1):121\u20138.","journal-title":"J Hepatol"},{"issue":"10234","key":"4019_CR26","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/S0140-6736(20)30937-5","volume":"395","author":"Z Varga","year":"2020","unstructured":"Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F, Moch H. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417\u20138.","journal-title":"Lancet"},{"issue":"4","key":"4019_CR27","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.jhep.2006.01.009","volume":"44","author":"P Deltenre","year":"2006","unstructured":"Deltenre P, Valla D-C. Ischemic cholangiopathy. J Hepatol. 2006;44(4):806\u201317.","journal-title":"J Hepatol"},{"issue":"1","key":"4019_CR28","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13054-015-0861-5","volume":"19","author":"S Leonhardt","year":"2015","unstructured":"Leonhardt S, Veltzke-Schlieker W, Adler A, Schott E, Hetzer R, Schaffartzik W, Tryba M, Neuhaus P, Seehofer D. Trigger mechanisms of secondary sclerosing cholangitis in critically ill patients. Crit Care. 2015;19(1):131.","journal-title":"Crit Care"},{"issue":"6","key":"4019_CR29","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1111\/j.1572-0241.2007.01118.x","volume":"102","author":"CM Gelbmann","year":"2007","unstructured":"Gelbmann CM, R\u00fcmmele P, Wimmer M, Hofst\u00e4dter F, G\u00f6hlmann B, Endlicher E, Kullmann F, Langgartner J, Sch\u00f6lmerich J. Ischemic-like cholangiopathy with secondary sclerosing cholangitis in critically ill patients. Off J Am Coll Gastroenterol ACG. 2007;102(6):1221\u20139.","journal-title":"Off J Am Coll Gastroenterol ACG"},{"issue":"5","key":"4019_CR30","first-page":"295","volume":"58","author":"AB Hill","year":"1965","unstructured":"Hill AB. The envirnonment and disease: association or Causation? Proc R Soc Med. 1965;58(5):295\u2013300.","journal-title":"Proc R Soc Med"},{"issue":"6","key":"4019_CR31","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1177\/0897190014525754","volume":"27","author":"G Bokor","year":"2014","unstructured":"Bokor G, Anderson PD. Ketamine: an update on its abuse. J Pharm Pract. 2014;27(6):582\u20136.","journal-title":"J Pharm Pract"},{"issue":"2","key":"4019_CR32","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1042\/cs0820169","volume":"82","author":"A Thune","year":"1992","unstructured":"Thune A, Jiveg\u00e5rd L, Pollard H, Moreau J, Schwartz JC, Svanvik J. Location of enkephalinase and functional effects of [Leu5] enkephalin and inhibition of enkephalinase in the feline main pancreatic and bile duct sphincters. Clin Sci. 1992;82(2):169\u201373.","journal-title":"Clin Sci"},{"issue":"3","key":"4019_CR33","first-page":"e52","volume":"52","author":"RS Lo","year":"2011","unstructured":"Lo RS, Krishnamoorthy R, Freeman JG, Austin AS. Cholestasis and biliary dilatation associated with chronic ketamine abuse: a case series. Singap Med J. 2011;52(3):e52-55.","journal-title":"Singap Med J"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-022-04019-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13054-022-04019-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-022-04019-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T14:09:46Z","timestamp":1653314986000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/s13054-022-04019-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,23]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["4019"],"URL":"https:\/\/doi.org\/10.1186\/s13054-022-04019-8","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,23]]},"assertion":[{"value":"8 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Both the prospective study protocol (ClinicalTrials.gov Identifier: NCT04410263, BASEC ID: ZH 2020-00646) and the post hoc analysis protocol (BASEC ID: ZH 2021-01617) were approved by the Swiss regional cantonal ethical commission. The study complies with the Declaration of Helsinki, the Guidelines on Good Clinical Practice (GCP-Directive) issued by the European Medicines Agency, the Swiss law and Swiss regulatory authority requirements. Written informed consent for participation from the patient or in case of death or disability, from the next of kin or legal representative, was sought for every patient included into the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication from the patient or in case of death or disability, from the next of kin or legal representative, was sought for every patient included into the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"148"}}